Letter: Medical Imports Placed At Risk By Likely Exit Path

In response to Jonathan Ford’s article yesterday, Regulation risk to medicines overplayed, Martin Sawer, Executive Director of HDA UK, wrote a letter to the Financial Times. His letter re-evaluates the impact of Brexit on the UK pharmaceutical industry. Printed in the Financial Times, the letter critiques Jonathan Ford’s underestimation of the potential negative impact on the medicines supply chain in the UK after leaving the European Union. As the Association that represents companies responsible for distributing 92% of NHS medicines, the HDA looks forward to working with the Government, regulators and supply chain partners to ensure that UK patients are not negatively affected by the vote to leave the European Union.

Letter: Medical Imports Placed At Risk By Likely Exit Path

From Factory to Pharmacy

As part of our mission to build awareness, understanding and appreciation of the vital importance of the healthcare distribution sector, we developed an infographic explaining the availability of medicines. It identifies the factors that can impact drug supply, as well as the measures that HDA members undertake day in, day out to help mitigate the risks of patients not receiving their medicines.

See the Infographic

Apply to become a Member

Membership of the HDA guarantees your organisation:

  • Access to leading policy and industry forums of debate and discussion
  • Invitations to a range of networking industry events organised through the year, including an Annual Conference and a Business Day
  • Representation on HDA working parties, including the Members’ Liaison Group
  • A daily Political and Media Bulletin and HDA Newsletters
  • Access to HDA policy documents and all sections of the HDA website
  • Branding and marketing opportunities
Apply Now

Already a Member?